4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Guardant Health, Inc. (GH) operates in the Diagnostics & Research industry and is headquartered in Palo Alto, United States with about 2,490 employees. Its market capitalization is roughly $22 billion. In the fiscal year ended 2025-12-31, GH reported $982M in revenue and ($416M) in net income.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Interactive charts & full statements → Open the GH valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $982M | $739M | $564M | $450M | — |
| Gross Profit | $633M | $449M | $337M | $293M | — |
| Operating Income (EBIT) | ($437M) | ($444M) | ($565M) | ($544M) | — |
| Net Income | ($416M) | ($436M) | ($479M) | ($655M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $302M | $281M | $265M | $232M | $204M |
| Gross Profit | $197M | $182M | $172M | $151M | $129M |
| Operating Income (EBIT) | ($121M) | ($121M) | ($99M) | ($106M) | ($111M) |
| Net Income | ($112M) | ($128M) | ($93M) | ($100M) | ($95M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $2.0B | $1.5B | $1.8B | $1.6B | — |
| Total Liabilities | $2.1B | $1.6B | $1.6B | $1.5B | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GH viewer.
About TickerBase · Data methodology & sources